Abstract
In Chronic Myeloid Leukemia (CML) patients achieving sustained deep molecular response (DMR) with tyrosine kinase inhibitor (TKI) may discontinue treatment. Treatment-free remission (TFR) occurs in a minority without predictive biomarkers. T-cell (LT) and Natural Killer (NK)-mediated antitumor immunity may impact TFR maintenance. We aim to correlate LT and NK phenotypes with measurable re…